WOC
RGLS

West Oak Capital’s Regulus Therapeutics RGLS Stock Holding History

West Oak Capital’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-700
Closed -$3K – 323
2020
Q1 		$3K Buy
700
+600
+600% +$5.23K ﹤0.01% 254
2019
Q4 		$1K Hold
100
– – ﹤0.01% 275
2019
Q3 		$1K Buy
+100
New +$814 ﹤0.01% 287

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

West Oak Capital's RGLS Position: Q2 2020 in Review

West Oak Capital sold out of Regulus Therapeutics (RGLS) in Q2 2020, closing a stake of 700 shares — an estimated $3K sold.

West Oak Capital first reported a position in RGLS in Q3 2019 and held it in 3 quarters. The position peaked at $3K in Q1 2020. 34 funds tracked by Wall St. Rank hold RGLS as of Q2 2020.

  • West Oak Capital reported no remaining Regulus Therapeutics position as of Q2 2020 after selling out during the quarter.
  • West Oak Capital sold 700 Regulus Therapeutics shares in Q2 2020, an estimated $3K.
  • West Oak Capital first reported a position in Regulus Therapeutics in Q3 2019 and held it in 3 quarters.
  • West Oak Capital's Regulus Therapeutics position peaked at $3K in Q1 2020.
  • 34 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2020.

Based on West Oak Capital's 13F filing for Q2 2020, filed 6 Jul 2020.